Monday Nov 25
Progenics Pharmaceuticals, Inc. Relaunching Registrational Trial Of...
Progenics Pharmaceuticals, Inc. today announced that it is resuming a phase 2b clinical study of safety and efficacy of a novel targeted radiotherapy, Azedraa , in patients suffering from pheochromocytomas.
European Journal of Human Genetics
Clinical utility gene card for: von Hippel-Lindau
Correspondence: Professor Dr J Decker, Clinic III—Hematology and Oncology, Medical School of Johannes Gutenberg University, Building 911 for Research and Development, Obere Zahlbacher Street 63, Mainz D 55131, Germany.
Pheochromocytoma: The Range of Appearances on Ultrasound, CT, MRI, and Functional Imaging
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.